References
- Lippross S, Loibl M, Hoppe S, Meury T, Benneker L, Alini M, Verrier S. Platelet released growth factors boost expansion of bone marrow derived CD34(+) and CD133(+) endothelial progenitor cells for autologous grafting. Platelets 2011 Apr 7. [Epub ahead of print].
- Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999; 14: 529–535
- Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007; 28: 4551–4560
- Anitua E, Sánchez M, Orive G, Andia I. Delivering growth factors for therapeutics. Trends Pharmacol Sci 2008; 29: 37–41
- Anitua E, Sánchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 2010; 62: 741–752
- Anitua E, Sánchez M, Orive G, Andía I. Shedding light in the controversial terminology for platelet rich products. J Biomed Mater Res A 2009; 90: 1262–1263
- Clemmonds DR. Structural and functional analysis of insulin-like growth factors. Br Med Bull 1989; 45: 465–480
- Thrailkill KM, Siddhanti SR, Fowlkes JL, Quarles LD. Differentiation of MC3T3-E1 osteoblasts is associated with temporal changes in the expression of IGF-1 and IGFBPs. Bone 1995; 17: 307–313
- Bikle DD, Harris J, Halloran BP, Roberts CT, Leroith D, Morey-Holton E. Expression of the genes for insulin-like growth factors and their receptors on bone during skeletal growth. Am J Physiol 1994; 267: E278–E286
- Meinel L, Zoidis E, Zapf J, Hassa P, Hottiger MO, Auer JA, Schneider R, Gander B, Luginbuehl V, Bettschart-Wolfisberger R, et al. Localized insulin-like growth factor 1 delivery to enhance new bone formation. Bone 2003; 33: 660–672
- Xian CJ, Foster BK. Repair of injured articular and growth plate cartilage using mesenchymal stem cells and chondrogenic gene therapy. Curr Stem Cell Res Ther 2006; 1: 213–229
- Benito M, Valverde AM, Lorenzo M. IGF-I: A mitogen also involved in differentiation processes in mammalian cells. Int J Biochem Cell Biol 1996; 28: 499–510
- Li J, Reed SA, Johnson SE. Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation. Exp Cell Res 2009; 315: 2284–2292
- Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: Mechanisms of NF-κB inhibition via HGF. J Cell Physiol 2010; 225: 757–766
- Iekushi K, Taniyama Y, Azuma J, Sanada F, Kusunoki H, Yokoi T, Koibuchi N, Okayama K, Rakugi H, Morishita R. Hepatocyte growth factor attenuates renal fibrosis through TGF-β1 suppression by apoptosis of myofibroblasts. J Hypertens 2010; 28: 2454–2461
- Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 2003; 163: 621–632
- Anitua E, Sánchez M, Zalduendo MM, de la Fuente M, Prado R, Orive G, Andía I. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif 2009; 42: 162–170
- Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts while inhibits and reverts TGF-β1-induced myodifferentiation. Invest Ophthalmol Vis Sci. in press.